FDA approves Padcev plus Keytruda for perioperative muscle-invasive bladder cancer
The COVID distortion is in its last year and oncology is being reported through
The ex-COVID base is now the correct modeling denominator, and inside it the oncology franchise carries the growth. The perioperative label matters more than its size suggests because it moves the product into the curative setting, where duration caps revenue per patient but the addressable population is defined by diagnosis rather than by metastatic progression.
The Food and Drug Administration approved an expanded indication for Padcev, known generically as enfortumab vedotin, in combination with Keytruda for the perioperative treatment of muscle-invasive bladder cancer. The approval covers patients eligible for cystectomy and follows a phase 3 trial in which the combination reduced the risk of recurrence, progression, or death by 42 percent versus observation. The label includes a 12-month duration for the neoadjuvant and adjuvant portions of treatment. Pfizer shares commercial rights in the United States through its Seagen acquisition and collaborates with Merck, which supplies Keytruda. Analysts estimate the expanded population adds 18,000 eligible patients annually in the United States. The approval was granted six weeks ahead of the target action date under priority review. The label continues to carry the existing peripheral neuropathy warning.
A 42 percent risk reduction in the curative setting at an early approval is the strongest label expansion Pfizer has received on the Seagen assets. The 12-month duration limits revenue per patient but broadens eligibility to 18,000 patients annually.
The oncology franchise is where the post-COVID story gets to be simple. A perioperative label is the highest-value real estate a cancer drug can win, and they got it early.
- Expanded indication covers perioperative treatment of muscle-invasive bladder cancer
- Phase 3 trial showed a 42 percent reduction in recurrence, progression, or death versus observation
- Approval granted six weeks ahead of target action date under priority review
- Approximately 18,000 additional eligible patients annually in the United States